Guideline-directed medical therapy assessment in heart failure patients undergoing percutaneous mitral valve repair.
Karl-Patrik Kresoja, Marianna Adamo, Karl-Phillipp Rommel...
https://pubmed.ncbi.nlm.nih.gov/38351672/Actively Recruiting
Led by University Medical Center Mainz · Updated on 2026-11-02
520
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating a treatment approach for patients with heart failure and reduced ejection fraction HFrEF who also have significant secondary mitral regurgitation. The trial aims to determine if early transcatheter edge-to-edge repair TEER of the mitral valve helps patients achieve faster and more complete guideline-directed medical therapy GDMT up-titration, and if this leads to better quality of life and clinical outcomes. Participants are randomly assigned to one of two groups. One group receives the TEER procedure within seven days of randomization followed by a structured GDMT up-titration regimen starting the day after the procedure. The other group receives the same GDMT regimen starting at randomization but without the early TEER. Medication doses are adjusted based on safety thresholds at several visits over 12 weeks. After 12 weeks, patients in the control group may opt to undergo TEER or mitral valve surgery if needed. During the study, participants undergo multiple assessments including evaluations of their medical therapy adherence, quality of life using the Kansas City Cardiomyopathy Questionnaire KCCQ, and clinical outcomes such as cardiovascular death or heart failure hospitalizations over 24 months. Medication safety and tolerability are carefully monitored at visits scheduled at 2, 4, 6, 8, 10, and 12 weeks. The trial lasts up to 24 months from randomization to assess the long-term impact of the treatments.
CONDITIONS
Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF
K
Karl-Patrik Kresoja, MD
V
Vera Jakobi
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Medical Center Mainz
Lead Sponsor
Abbott
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants are randomly assigned to receive the mitral valve repair procedure plus medication or medication alone. They follow a structured medication adjustment plan over 12 weeks with monitoring for safety and tolerability.
Visits at 2, 4, 6, 8, 10, and 12 weeks
Duration - 24 months
Participants are monitored for clinical outcomes including cardiovascular events and quality of life for up to 24 months from randomization.
Periodic assessments up to 24 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Karl-Patrik Kresoja, Marianna Adamo, Karl-Phillipp Rommel...
https://pubmed.ncbi.nlm.nih.gov/38351672/Marianna Adamo, Daniela Tomasoni, Lukas Stolz...
https://pubmed.ncbi.nlm.nih.gov/37100553/Milton Packer, Marco Metra
https://pubmed.ncbi.nlm.nih.gov/32432391/Gregg W Stone, JoAnn Lindenfeld, William T Abraham...
https://pubmed.ncbi.nlm.nih.gov/30280640/Stefan D Anker, Tim Friede, Ralph-Stephan von Bardeleben...
https://pubmed.ncbi.nlm.nih.gov/39216092/University Medical Center Mainz
Lead Sponsor
Abbott
Collaborating Sponsor